JP2020503357A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503357A5
JP2020503357A5 JP2019536222A JP2019536222A JP2020503357A5 JP 2020503357 A5 JP2020503357 A5 JP 2020503357A5 JP 2019536222 A JP2019536222 A JP 2019536222A JP 2019536222 A JP2019536222 A JP 2019536222A JP 2020503357 A5 JP2020503357 A5 JP 2020503357A5
Authority
JP
Japan
Prior art keywords
composition according
salt
synthetic
active ingredient
caprilate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503357A (ja
JP7281815B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012261 external-priority patent/WO2018129097A1/en
Publication of JP2020503357A publication Critical patent/JP2020503357A/ja
Publication of JP2020503357A5 publication Critical patent/JP2020503357A5/ja
Priority to JP2023018922A priority Critical patent/JP7466238B2/ja
Application granted granted Critical
Publication of JP7281815B2 publication Critical patent/JP7281815B2/ja
Priority to JP2024047771A priority patent/JP2024075724A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536222A 2017-01-03 2018-01-03 医薬化合物及び栄養補給剤 Active JP7281815B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023018922A JP7466238B2 (ja) 2017-01-03 2023-02-10 医薬化合物及び栄養補給剤
JP2024047771A JP2024075724A (ja) 2017-01-03 2024-03-25 医薬化合物及び栄養補給剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762441908P 2017-01-03 2017-01-03
US62/441,908 2017-01-03
PCT/US2018/012261 WO2018129097A1 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018922A Division JP7466238B2 (ja) 2017-01-03 2023-02-10 医薬化合物及び栄養補給剤

Publications (3)

Publication Number Publication Date
JP2020503357A JP2020503357A (ja) 2020-01-30
JP2020503357A5 true JP2020503357A5 (cg-RX-API-DMAC10.html) 2021-02-12
JP7281815B2 JP7281815B2 (ja) 2023-05-26

Family

ID=62790943

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019536222A Active JP7281815B2 (ja) 2017-01-03 2018-01-03 医薬化合物及び栄養補給剤
JP2023018922A Active JP7466238B2 (ja) 2017-01-03 2023-02-10 医薬化合物及び栄養補給剤
JP2024047771A Pending JP2024075724A (ja) 2017-01-03 2024-03-25 医薬化合物及び栄養補給剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023018922A Active JP7466238B2 (ja) 2017-01-03 2023-02-10 医薬化合物及び栄養補給剤
JP2024047771A Pending JP2024075724A (ja) 2017-01-03 2024-03-25 医薬化合物及び栄養補給剤

Country Status (14)

Country Link
US (2) US20190336472A1 (cg-RX-API-DMAC10.html)
EP (1) EP3565539A4 (cg-RX-API-DMAC10.html)
JP (3) JP7281815B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190103302A (cg-RX-API-DMAC10.html)
CN (1) CN110121337A (cg-RX-API-DMAC10.html)
AU (2) AU2018206564B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019013743A2 (cg-RX-API-DMAC10.html)
CA (1) CA3049226A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019001832A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019008176A2 (cg-RX-API-DMAC10.html)
EA (1) EA201991641A1 (cg-RX-API-DMAC10.html)
IL (1) IL267831A (cg-RX-API-DMAC10.html)
MX (1) MX2019007968A (cg-RX-API-DMAC10.html)
WO (1) WO2018129097A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180781B2 (en) * 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
WO2019144221A1 (en) * 2018-01-29 2019-08-01 Solantech Inc. Methods of treating and/or preventing bedsores using nabilone
AU2019357608A1 (en) * 2018-10-10 2021-05-27 Tilray, Inc. Methods and formulations for treating chemotherapy-induced nausea and vomiting
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
EP3946262B1 (en) 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
JP2023505351A (ja) 2019-12-09 2023-02-08 ニコベンチャーズ トレーディング リミテッド 口腔用組成物のための薬剤
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
CN113040337B (zh) * 2021-04-22 2022-12-09 四川大学 一种熏肉制品及其制备方法
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
ES2687098T3 (es) * 2010-11-25 2018-10-23 Aop Orphan Pharmaceuticals Ag Composiciones de disgregación rápida que comprenden nabilona y beta ciclodextrina metilada de manera aleatoria
EP2747563A4 (en) * 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CN109069475B (zh) * 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201991641A1 (ru) 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки

Similar Documents

Publication Publication Date Title
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
BRPI0813044A2 (pt) "composto, composição fungicida e método para o controle do fungo fitopatogênico de culturas"
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
JP2016540809A5 (cg-RX-API-DMAC10.html)
SG10201804024VA (en) Formulations of azaindole compounds
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
JP2013518036A5 (cg-RX-API-DMAC10.html)
EP2151241A4 (en) STABLE SOLID PREPARATION WITH 4,5-EPOXYMORPHINANE DERIVATIVE
WO2009007137A3 (en) Pharmaceutical composition for topical application of poorly soluble compounds
HRP20160802T1 (hr) Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka
JP2019526634A5 (cg-RX-API-DMAC10.html)
RU2010110603A (ru) Высококонцентрированные препараты 1-метилгептилового эфира флуроксипира, стабильные при низких температурах
RU2014116395A (ru) Соединения, композиции и способы для снижения или устранения горького вкуса
JP2023116514A (ja) 医療用葉酸塩
HRP20190783T1 (hr) Farmaceutske formulacije
CN1203600A (zh) 二氨基嘧啶,含它们的药物组合物和其作为抗菌药物的用途
EP1634883A4 (en) 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLO-2,3-PYRIMIDIN-4-ONDERIVATES, THEIR PREPARATION AND PHARMACEUTICAL USE
CA2546643A1 (en) Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
EA202190036A1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение
RU2008121716A (ru) Препараты
HRP20200472T1 (hr) Liječenje alopecije areate
KR870004029A (ko) 피리도[1,2-a]피리미딘 유도체의 제조법 및 이를 유효 성분으로 하는 알레르기 질환 치료약
JP5611089B2 (ja) 水性液体口腔用組成物
AR063467A1 (es) Preparacion de sales farmaceuticas del acido 3-o-(3',3'-dimetilsuccinil)betulinico; sales del mismo, composiciones farmaceuticas que las comprenden y el empleo de estas en el tratamiento de infecciones con vih.